Glucose transporter-1 expression in CD133+ laryngeal carcinoma Hep-2 cells

Molecular Medicine Reports

Volumn 8, Issue 6, 2013, Pages 1695-1700

  Chen, Xiao Hong ^a,c   Bao, Yang Yang ^a   Zhou, Shui Hong ^a   Wang, Qin Ying ^a   Wei, Yan ^a   Fan, Jun ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c The Second Hospital of Jiaxing City   (China)

Author keywords

Cancer stem cell; CD133; Glucose transporter 1; Laryngeal carcinoma; Warburg effect

Indexed keywords

BETA TUBULIN; CD133 ANTIGEN; GLUCOSE TRANSPORTER 1; MESSENGER RNA; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; SLC2A1 PROTEIN, HUMAN;

ARTICLE; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; HEP 2 CELL; HUMAN; HUMAN CELL; LARYNX CARCINOMA; LIGHT ABSORPTION; PROTEIN EXPRESSION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; LARYNX TUMOR; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTIGENS, CD; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLYCOPROTEINS; HUMANS; LARYNGEAL NEOPLASMS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84893806466     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1740     Document Type: Article

References (33)

1. Yang JP, Liu Y, Zhong W, Yu D, Wen LJ and Jin CS: Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma. Chin Med J (Engl) 124: 1055-1060, 2011.
2. Chen H, Zhou L, Dou T, Wan G, Tang H and Tian J: BMI1'S maintenance of the proliferative capacity of laryngeal cancer stem cells. Head Neck 33: 1115-1125, 2011.
3. Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ and Maccallum J: In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 31: 94-101, 2009.
4. Zhou L, Wei X, Cheng L, Tian J and Jiang JJ: CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 117: 455-460, 2007.
5. Piao LS, Hur W, Kim TK, et al: CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 315: 129-137, 2012.
6. Ke CC, Liu RS, Yang AH, et al: CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging 40: 61-71, 2013.
7. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
8. Liu YP, Yang CJ, Huang MS, et al: Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 73: 406-416, 2013.
9. Neth P, Ries C, Karow M, Egea V, Ilmer M and Jochum M: The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 3: 18-29, 2007.
10. Huang D, Gao Q, Guo L, et al: Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18: 465-473, 2009.
11. Gangopadhyay S, Nandy A, Hor P and Mukhopadhyay A: Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 13: 7-15, 2013.
12. Ping YF, Yao XH, Jiang JY, et al: The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol 224: 344-354, 2011.
13. Bensinger SJ and Christofk HR: New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 23: 352-361, 2012.
14. Zhao K, Luo XM, Zhou SH, et al: 18F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor. Cancer Biother Radiopharm 27: 685-693, 2012.
15. Hammoudi N, Ahmed KB, Garcia-Prieto C and Huang P: Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer 30: 508-525, 2011.
16. Varum S, Rodrigues AS, Moura MB, et al: Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One 6: e20914, 2011.
17. Han MW, Lee HJ, Cho KJ, et al: Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck 34: 1395-1402, 2012.
18. Li XF, Ma Y, Sun X, Humm JL, Ling CC and O'Donoghue JA: High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med 51: 632-638, 2010.
19. Alakus H, Batur M, Schmidt M, et al: Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 31: 532-538, 2010.
20. Nagamatsu A, Umesaki N, Li L and Tanaka T: Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep 23: 1069-1076, 2010.
21. Zhou S, Wang S, Wu Q, Fan J and Wang Q: Expression of glucose transporter-1 and -3 in the head and neck carcinoma - the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec 70: 189-194, 2008.
22. Li LF, Zhou SH, Zhao K, et al: Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm 23: 701-714, 2008.
23. Mai HM, Zheng JW, Wang YA, et al: CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Chin Med J (Engl) 126: 88-94, 2013.
24. Loda M, Xu X, Pession A, Vortmeyer A and Giangaspero F: Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system. Neuropathol Appl Neurobiol 26: 91-97, 2000.
25. Wu XH, Chen SP, Mao JY, Ji XX, Yao HT and Zhou SH: Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. Oncol Lett 5: 261-266, 2013.
26. Xu YY, Bao YY, Zhou SH and Fan J: Effect on the expression of MMP-2, MT-MMP in laryngeal carcinoma Hep-2 cell line by antisense glucose transporter-1. Arch Med Res 43: 395-401, 2012.
27. Zhou SH, Fan J, Chen XM, Cheng KJ and Wang SQ: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 31: 1624-1633, 2009.
28. Korkeila E, Jaakkola PM, Syrjänen K, Pyrhönen S and Sundström J: Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer. Anticancer Res 31: 311-315, 2011.
29. Chiba I, Ogawa K, Morioka T, et al: Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Oncol Lett 2: 21-28, 2011.
30. Kunkel M, Moergel M, Stockinger M, et al: Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 43: 796-803, 2007.
31. Eckert AW, Kappler M, Schubert J and Taubert H: Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac Surg 16: 189-196, 2012.
32. Rademakers SE, Lok J, van der Kogel AJ, Bussink J and Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11: 167, 2011.
33. Cao X, Fang L, Gibbs S, et al: Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59: 495-505, 2007.